Transcription of Lynparza Prescribing Information
{{id}} {{{paragraph}}}
Example: marketing
Lynparza Prescribing Information
US-54700. HIGHLIGHTS OF Prescribing Information Prostate cancer These highlights do not include all the Information needed to use Lynparza safely for the treatment of adult patients with deleterious or suspected deleterious germline and effectively. See full Prescribing Information for Lynparza . or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior Lynparza (olaparib) tablets, for oral use treatment with enzalutamide or abiraterone. Select patients for therapy based on an Initial Approval: 2014 FDA-approved companion diagnostic for Lynparza .
deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1)].
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: